The off-label use of various drugs to treat Covid-19 in France is associated with cardiac adverse drug reactions (ADRs), according to study results reported in *Therapies*, which mostly involve hydroxychloroquine.

The study investigated all cardiac ADRs reported to the French Pharmacovigilance Network between 27 March 2020 and 27 April 2020. There were 120 patients with 131 reported cardiac ADRs, with 110 reports (91.7%) classified as serious. The mean patient age was 64.3 years; 76.7% of patients were male. Six reports derived from self-medication. Almost all events (96.7%) occurred in the hospital setting. Drug causality was assessed as likely or very likely in 11 cases, and plausible in 66 cases.

The reports mostly involved hydroxychloroquine (n=103), followed by azithromycin (n=64), lopinavir/ritonavir (n=17) and chloroquine (n=3). Co-treatment with azithromycin or lopinavir/ritonavir occurred in 60 and 1 hydroxychloroquine recipients, respectively. For 37 reports, patients were also receiving other drugs associated with QTc prolongation.

There were 8 sudden, unexplained or aborted deaths (6.1%), including 4 cardiac arrests, all in hydroxychloroquine recipients. Ventricular arrhythmias were reported in 8 cases (6.1%), and there were 90 reports of a prolonged QTc interval (68.7%), with 58 reports classified as serious; 48 reports had a QTc value ≥500ms. In addition, there were 20 cases of severe conduction disorders (15.3%) and 5 reports (3.8%) of other cardiac ADRs comprising heart failure, supraventricular tachycardia, chest pain, and suffocating and palpitation sensations in a patient with asthma.

The authors conclude that \"off-label\" use of treatments in Covid-19 increases the risk of cardiac ADRs, some of them avoidable\", and that \"even if these drugs are perceived as familiar, they are used in patients with added risk factors caused by infection\". They note that \"precautions should be taken to mitigate the risk, even if they will be proven efficacious\", and that \"in the uncertain times we are living, it remains paramount to base one\'s prescription on a clear and positive benefit-risk balance of any chosen drug\".
